Tumor Immunology Research Task
(Redirected from Cancer Immunology)
Jump to navigation
Jump to search
A Tumor Immunology Research Task is an Immunology Research Task that focuses on tumors (typically malignant tumors).
- See: Immunotherapy, Antigen, Targeted Therapy, Vaccine, Antibody, Tumor Marker, Diagnostic Test, Immunosurveillance.
References
2014
- (Wikipedia, 2014) ⇒ http://en.wikipedia.org/wiki/Cancer_immunology Retrieved:2014-8-2.
- Cancer immunology is a branch of immunology that studies interactions between the immune system and cancer cells (also called tumors or malignancies). It is a growing field of research that aims to discover innovative cancer immunotherapies to treat and retard progression of the disease. The immune response, including the recognition of cancer-specific antigens, is of particular interest in the field as knowledge gained drives the development of targeted therapy (such as new vaccines and antibody therapies) and tumor marker-based diagnostic tests. For instance in 2007, Ohtani published a paper finding tumour infiltrating lymphocytes to be quite significant in human colorectal cancer. The host was given a better chance at survival if the cancer tissue showed infiltration of inflammatory cells, in particular those prompting lymphocytic reactions. The results yielded suggest some extent of anti-tumour immunity is present in colorectal cancers in humans.
Over the past 10 years there has been notable progress and an accumulation of scientific evidence for the concept of cancer immunosurveillance and immunoediting based on (i) protection against development of spontaneous and chemically-induced tumors in animal systems and (ii) identification of targets for immune recognition of human cancer.
- Cancer immunology is a branch of immunology that studies interactions between the immune system and cancer cells (also called tumors or malignancies). It is a growing field of research that aims to discover innovative cancer immunotherapies to treat and retard progression of the disease. The immune response, including the recognition of cancer-specific antigens, is of particular interest in the field as knowledge gained drives the development of targeted therapy (such as new vaccines and antibody therapies) and tumor marker-based diagnostic tests. For instance in 2007, Ohtani published a paper finding tumour infiltrating lymphocytes to be quite significant in human colorectal cancer. The host was given a better chance at survival if the cancer tissue showed infiltration of inflammatory cells, in particular those prompting lymphocytic reactions. The results yielded suggest some extent of anti-tumour immunity is present in colorectal cancers in humans.
2003
- (Lizée et al., 2003) Gregory Lizée, Genc Basha, Jacqueline Tiong, Jean-Pierre Julien, Meimei Tian, Kaan E. Biron, and Wilfred A. Jefferies. (2003). “Control of dendritic cell cross-presentation by the major histocompatibility complex class I cytoplasmic domain.” In: Nature immunology, 4(11).